Notably, PMEL and MLANA are currently used as diagnostic biomarkers, and we confirmed that the knockout of MGRN1 in MM cells increased genomic damage and led to a comparable transcriptomic profile. This evidence concerns the gene MGRN1 and Miyoshi myopathy.